Glaukos plunges 6% on EPS miss despite revenue surge
Non-cash impairment charge offsets 36% revenue growth in glaucoma treatment business
Glaukos Corporation shares fell more than 6% in Tuesday trading after the ophthalmic medical technology company reported fourth-quarter earnings that missed expectations despite delivering revenue growth that shattered analyst estimates.
The San Clemente, California-based company posted quarterly revenue of $143.1 million, beating Wall Street forecasts by 16.8% and surging 36% year-over-year. The top-line performance was driven primarily by glaucoma treatment sales, which jumped 42% compared to the same period last year.
However, the strong revenue performance was overshadowed by an earnings-per-share miss. The company reported a loss of 28 cents per share, worse than the expected 26-cent loss, primarily due to a non-cash impairment charge of $112.9 million taken during the quarter. On a non-GAAP basis, losses narrowed to 28 cents per share from 40 cents in the prior-year quarter.
The market reaction highlighted investor concerns about profitability despite the company's expanding commercial footprint. Glaukos shares, which traded at $106.64 at Tuesday's close, remain well below their 52-week high of $161.78 but have more than doubled from their yearly low of $73.16.
Analysts maintain an overwhelmingly bullish outlook on the stock despite the earnings miss. The company currently carries 14 buy ratings versus just one sell, with an average target price of $132.71—roughly 24% above current levels. This suggests Wall Street believes the long-term growth story remains intact, with the impairment charge viewed as a one-time event rather than a structural issue.
Glaukos, which specializes in developing therapies for glaucoma, corneal disorders, and retinal diseases, reaffirmed its 2026 revenue guidance of $600 million to $620 million. This guidance represents continued growth from the $469.8 million in trailing twelve-month revenue reported by the company, underscoring management's confidence in sustained commercial execution.
The 42% surge in glaucoma product sales indicates accelerating adoption of the company's core therapies in a market with significant unmet medical need. Glaucoma affects more than 70 million people worldwide and is a leading cause of irreversible blindness, creating substantial commercial opportunity for effective treatment innovations.
The mixed quarterly results illustrate the typical tension between investment-heavy growth companies and short-term profitability expectations. Glaukos's 38.1% year-over-year revenue growth demonstrates strong market demand for its products, but the substantial impairment charge—likely related to intangible assets or goodwill—highlighted the balance sheet challenges that can accompany rapid expansion in medical technology.
With the company operating at a 13.38 price-to-sales ratio, investors are clearly paying a premium for growth. The question for markets in coming quarters will be whether Glaukos can convert its expanding revenue base into sustainable profitability as it scales its commercial operations.